<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __) *
CV THERAPEUTICS, INC.
---------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
------------------------------
(Title of Class of Securities)
126667 10 4
--------------
(CUSIP Number)
May 5, 1999
-----------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
Page 1 of 5 Pages
<PAGE> 2
- --------------------- -----------------
CUSIP No. 126667 10 4 Schedule 13G Page 2 of 5 Pages
- --------------------- -----------------
- --------------------------------------------------------------------------------
1) NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).
Quintiles Transnational Corp.
I.R.S. Employer Identification No.: 56-1714315
- --------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [ ]
(b) [ ]
NOT APPLICABLE
- --------------------------------------------------------------------------------
3) SEC USE ONLY
- --------------------------------------------------------------------------------
4) CITIZENSHIP OR PLACE OF ORGANIZATION
North Carolina
- --------------------------------------------------------------------------------
5) SOLE VOTING POWER
NUMBER OF 1,043,705
SHARES -----------------------------------------------------
BENEFICIALLY 6) SHARED VOTING POWER
OWNED BY -0-
EACH -----------------------------------------------------
REPORTING 7) SOLE DISPOSITIVE POWER
PERSON 1,043,705
WITH: -----------------------------------------------------
8) SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,043,705
- --------------------------------------------------------------------------------
10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
NOT APPLICABLE [ ]
- --------------------------------------------------------------------------------
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.49%
- --------------------------------------------------------------------------------
12) TYPE OF REPORTING PERSON (See Instructions)
CO
<PAGE> 3
- --------------------- -----------------
CUSIP No. 126667 10 4 Schedule 13G Page 3 of 5 Pages
- --------------------- -----------------
Item 1.
(a) Name of Issuer
CV Therapeutics, Inc.
(b) Address of Issuer's Principal Executive Offices
3172 Porter Drive
Palo Alto, California 94304
Item 2.
(a) Name of Person Filing
Quintiles Transnational Corp.
(b) Address of Principal Business Office or, if none, Residence
4709 Creekstone Drive
Riverbirch Building, Suite 200
Durham, North Carolina 27703
(c) Citizenship:
North Carolina
(d) Title of Class of Securities
Common stock, par value $.001 per share
(e) CUSIP Number
126667 10 4
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:
As of May 5, 1999, the reporting person beneficially owned 1,043,705
shares of Common Stock of CV Therapeutics, Inc.
<PAGE> 4
- --------------------- -----------------
CUSIP No. 126667 10 4 Schedule 13G Page 4 of 5 Pages
- --------------------- -----------------
(b) Percent of Class:
Such 1,043,705 shares of Common Stock are 8.49% of the 12,291,960
shares of Common Stock outstanding as of May 5, 1999, as reported by CV
Therapeutics, Inc. to the reporting person.
(c) Number of shares as to which such person has:
<TABLE>
<S> <C>
(i) sole power to vote or to direct the vote: 1,043,705
(ii) shared power to vote or to direct the vote: -0-
(iii) sole power to dispose or to direct the disposition of: 1,043,705
(iv) shared power to dispose or to direct the disposition of: -0-
</TABLE>
Item 5. Ownership of Five Percent or Less of a Class
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
<PAGE> 5
- --------------------- -----------------
CUSIP No. 126667 10 4 Schedule 13G Page 5 of 5 Pages
- --------------------- -----------------
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: May 11, 1999
Signature: Quintiles Transnational Corp.
By: /s/ John Russell
--------------------------------------
Name: John Russell
Title: Vice President and General Counsel
